Abstract
Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Infectious Disorders - Drug Targets
Title:Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Volume: 15 Issue: 1
Author(s): Mohamed Jawed Ahsan, Mohammad Yousuf Ansari, Sabina Yasmin, Surender Singh Jadav, Pradeep Kumar, Shiv Kumar Garg, Ajay Aseri and Habibullah Khalilullah
Affiliation:
Keywords: Antitubercular agents, review, tuberculosis, tubercular vaccines, tuberculosis diagnosis.
Abstract: Tuberculosis (TB), a dreadful disease is one of the most important health problems worldwide, and is responsible for approximately 1.3 million death tolls in 2012. DOTS is the currently used drug therapy in TB and the long term drug regimens and patients’ poor compliance lead to emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB, which invigorates the research efforts to address the urgent need for the quick diagnosis and for newer antitubercular agents and vaccines to completely eradicate TB. Today we have at least 20 new diagnostic test platforms, 14 TB vaccine candidates in clinical trials and over 35 candidates in preclinical development, and among the antitubercular agents under clinical investigation, 4 anti-TB agents are in Phase III (efficacy) trials and 7 anti-TB agents are in Phase II, early bactericidal activity and sputum culture conversion trials (rifapentine is in a Phase II and a Phase III trial), 5 anti-TB agents in preclinical development and 3 anti-TB agents in Good Laboratory Practice toxicity evaluation. Recently US FDA has approved TMC207 as a part of combination therapy to treat adults with MDR pulmonary TB in the absence of other alternatives. We provide here the concise review on the chemical entities currently in the clinical trials, the new vaccines in the developmental pipeline, and the new diagnostic test.
Export Options
About this article
Cite this article as:
Jawed Ahsan Mohamed, Yousuf Ansari Mohammad, Yasmin Sabina, Jadav Surender Singh, Kumar Pradeep, Kumar Garg Shiv, Aseri Ajay and Khalilullah Habibullah, Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526514666140923153329
DOI https://dx.doi.org/10.2174/1871526514666140923153329 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Experimental and Clinical Studies on Rifacinna® - The New Effective Antituberculous Drug (Review)
Recent Patents on Anti-Infective Drug Discovery Microwave Induced One Pot Ugi Multicomponent Reaction of Fluoroquino Lone Scaffolds: Their Biological Evaluation
Current Green Chemistry Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Current Topics in Medicinal Chemistry Meet Our Associate Editor
Anti-Cancer Agents in Medicinal Chemistry Membrane Binding Mechanism of Yeast Mitochondrial Peripheral Membrane Protzein TIM44
Protein & Peptide Letters Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Anti-Tuberculosis Activity of α-Helical Antimicrobial Peptides: De Novo Designed L- and D-Enantiomers Versus L- and D-LL37
Protein & Peptide Letters Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Recent Patents in Autophagy and Immune Response
Recent Patents on Inflammation & Allergy Drug Discovery Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials In Silico Identification of Human miR 3654 and its Targets Revealed its Involvement in Prostate Cancer Progression
MicroRNA Green Synthesis of N-doped Graphene Nanosheets by Cow Urine
Current Graphene Science (Discontinued) The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Studies on Chemistry, Spectroscopy and Antioxidant Activities of Chromium(III)-Hydrazide Complexes
Medicinal Chemistry Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity
Current Pharmaceutical Design Performance of Genotype MTBDRplus in the Detection of Resistance to Rifampicin and Isoniazid Among Clinical Mycobacteria Isolates in Ilorin, Nigeria
Current HIV Research Effect of Sulfonamides on the Electrophysical Properties of Bacterial Cells
Anti-Infective Agents QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Current Pharmaceutical Design